FT Logo (1).png
Field Trip Health Ltd. Granted US Patent Covering Novel Psychedelic Molecule FT-104
April 05, 2022 07:51 ET | Field Trip Health, Ltd.
TORONTO, April 05, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced...
FT Logo (1).png
Field Trip Health Ltd. to Participate in Maxim Group 2nd Annual Virtual Growth Conference
March 23, 2022 08:00 ET | Field Trip Health, Ltd.
TORONTO, March 23, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies,...
FT Logo (1).png
Field Trip Health Ltd. to Participate in 34th Annual Roth Conference in March 2022
March 09, 2022 08:00 ET | Field Trip Health, Ltd.
TORONTO, March 09, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies,...
FT Logo (1).png
Field Trip Health Ltd. Reports Third Fiscal Quarter 2022 Financial Results and Provides Business Update
February 15, 2022 17:15 ET | Field Trip Health, Ltd.
Earned patient services revenues of $1,360,811, an increase of 50% over the prior quarter and 330% year over year.At December 31, 2021, Field Trip had approximately $74.5 million in unrestricted cash...
FT Logo (1).png
Field Trip Health Ltd. Schedules Third Fiscal Quarter 2022 Financial Results Conference Call for February 16, 2022 at 8:30 AM ET
February 01, 2022 08:00 ET | Field Trip Health, Ltd.
TORONTO, Feb. 01, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies,...
FT Logo (1).png
Field Trip Health Ltd. to Participate in Citi’s Psychedelic Drug Video Call Series
January 18, 2022 08:00 ET | Field Trip Health, Ltd.
TORONTO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies,...
FT Logo (1).png
Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development
January 11, 2022 10:00 ET | Field Trip Health, Ltd.
TORONTO, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced...
FT Logo (1).png
Field Trip Announces Intention to Make Applications on Behalf of Patients to Health Canada’s Special Access Program (SAP) for Access to Psilocybin and MDMA-Assisted Therapies
January 06, 2022 08:00 ET | Field Trip Health, Ltd.
TORONTO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced...
FT Logo (1).png
Field Trip Health Ltd. to Participate in H.C. Wainwright Bioconnect Virtual Conference in January 2022
January 05, 2022 07:30 ET | Field Trip Health, Ltd.
TORONTO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies,...
FT Logo (1).png
Field Trip Launches Site Management Organization (SMO) Services, Hires Stéphan Côté as Head of Quality
December 14, 2021 07:30 ET | Field Trip Health, Ltd.
TORONTO, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (NASDAQ: FTRP, TSX: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, today announced...